Evidence map›Paper›PMID 25801239›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015

Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast.

Li Wang, Wei Zhang, Shuhua Lyu, Xia Liu, Tongxian Zhang, Shan Liu, Ying Qin, Xiaoqi Tian, Yun Niu

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP.Laboratory investigation; a journal of technical methods and pathology · 2019
    Observational
  15. Microinvasive Carcinoma versus Ductal CarcinomaJournal of breast cancer · 2018
    Article
  16. Article
  17. Long term prognosis of ductal carcinomaInternational journal of clinical and experimental pathology · 2018
    Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Li WangDepartment of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China.
Wei Zhang
Shuhua Lyu
Xia Liu
Tongxian Zhang
Shan Liu
Ying Qin
Xiaoqi Tian
Yun Niu
Tianjin Medical University Cancer Institute and Hospital · CNTianjin Nankai Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with microinvasive carcinoma often have favorable prognosis, but it remains unclear whether this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior distinct from those of ductal carcinoma in situ (DCIS). The study is a retrospective analysis of a large patient cohort from a single institution. One hundred and thirty one microinvasive carcinoma and 451 DCIS cases were collected. ER, PR, HER2, and Ki67 were examined by immunohistochemistry in pathological sections. We assessed the clinicopathologic characteristics, molecular features, and survival status of microinvasive carcinoma and compared to those of DCIS. Microinvasive carcinoma differed from DCIS with respect to tumor size, lymph node status, and initial presentation (P < 0.05). There was a significant difference in nuclear grade among microinvasive carcinoma of different molecular subtype (P < 0.05). The clinicalpathologic features and outcomes of patients with microinvasive carcinoma were similar to those with DCIS. The 5-year OS rate for microinvasive carcinoma and DCIS patients was 99.0 and 99.2%, respectively. A combination of pathologic, clinical, and molecular factors may ultimately reveal more powerful and robust measures for disease classification than any one modality alone. Microinvasive carcinoma does not significantly predict for worse DFS or OS in comparison with patients with DCIS.

Indexed as

Pathology, MolecularAdultAgedCarcinoma, Ductal, BreastDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenMiddle AgedNeoplasm InvasivenessERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaKi-67 Antigen

Identifiers

PMID25801239
OpenAlexW2043482396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.